{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:58Z","timestamp":1793814118856,"version":"4.6.1"},"reference-count":78,"publisher":"Wiley","issue":"3-4","license":[{"start":{"date-parts":[[2007,1,2]],"date-time":"2007-01-02T00:00:00Z","timestamp":1167696000000},"content-version":"vor","delay-in-days":123,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Drug Reviews"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Glycosaminoglycans (GAGs) are the most abundant group of heteropolysaccharides found in the body. These long unbranched molecules contain a repeating disaccharide unit. GAGs are located primarily in the extracellular matrix or on the surface of cells. These molecules serve as lubricants in the joints while at the same time providing structural rigidity to cells. Sulodexide is a highly purified glycosaminoglycan composed of a fast mobility heparin fraction as well as dermatan sulfate. Sulodexide differs from other glycosaminoglycans, like heparin, by having a longer half\u2010life and a reduced effect on systemic clotting and bleeding. In addition, sulodexide demonstrates a lipolytic activity that is increased in comparison to heparin. Oral administration of sulodexide results in the release of tissue plasminogen activator and an increase in fibrinolytic activities. An increasing body of research has demonstrated the safety and efficacy of sulodexide in a wide range of vascular pathologies.<\/jats:p>","DOI":"10.1111\/j.1527-3466.2006.00214.x","type":"journal-article","created":{"date-parts":[[2007,1,2]],"date-time":"2007-01-02T17:57:03Z","timestamp":1167760623000},"page":"214-226","source":"Crossref","is-referenced-by-count":56,"title":["Sulodexide: A Renewed Interest in This Glycosaminoglycan"],"prefix":"10.1111","volume":"24","author":[{"given":"D. Adam","family":"Lauver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict R.","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"568","article-title":"One year course of oral sulodexide in the management of diabetic nephropathy","volume":"18","author":"Achour A","year":"2005","journal-title":"J Nephrol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(84)90108-7"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.162232399"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02591420"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.040600"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0008-6363(96)88632-9"},{"key":"e_1_2_1_8_2","first-page":"309","article-title":"Prevention and treatment of thrombosis: novel strategies arising from our understanding the healthy endothelium","volume":"105","author":"Buchanan MR","year":"1993","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(94)90267-4"},{"issue":"1","key":"e_1_2_1_10_2","first-page":"49","article-title":"Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide","volume":"19","author":"Callas DD","year":"1993","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"e_1_2_1_11_2","first-page":"9","article-title":"Structural features and binding properties of chondroitin sulfates, dermatan sulfate, and heparan sulfate","volume":"17","author":"Casu B.","year":"1991","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_12_2","first-page":"484","article-title":"Increased glomerular alpha 1 (IV) collagen expression and deposition in long\u2010term diabetic rats is prevented by chronic glycosaminoglycan treatment","volume":"74","author":"Ceol M","year":"1996","journal-title":"Lab Invest"},{"key":"e_1_2_1_13_2","first-page":"225","article-title":"Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: Effects of the glycosaminoglycan sulodexide","volume":"19","author":"Ceriello A","year":"1993","journal-title":"Diabete Metab"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1001909"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331970605700108"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613116"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.3033"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000140763.51679.D9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(03)00246-9"},{"key":"e_1_2_1_20_2","first-page":"215","article-title":"Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial","volume":"14","author":"Crepaldi G","year":"1986","journal-title":"Monogr Atheroscler"},{"key":"e_1_2_1_21_2","first-page":"189","article-title":"Sulodexide oral administration influences blood viscosity and fibrinolysis","volume":"18","author":"Crepaldi G","year":"1992","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_1_22_2","first-page":"1513","article-title":"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats","volume":"35","author":"Cristofori M","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939550"},{"key":"e_1_2_1_24_2","first-page":"55","article-title":"Isolation and characterization of C\u2010reactive protein and serum amyloid P component in the rat","volume":"45","author":"De Beer FC","year":"1982","journal-title":"Immunology"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00285287"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600620402"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331970405500302"},{"issue":"4","key":"e_1_2_1_29_2","first-page":"64","article-title":"Microalbuminuria, endothelial dysfunction and cardiovascular risk","volume":"26","author":"Feldt\u2010Rasmussen B.","year":"2000","journal-title":"Diabetes Metab"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.75.4.701"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203193261205"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.288"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000014254.87188.E5"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.335"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/107424849600100305","article-title":"Reduction of myocardial necrosis after glycosaminoglycan administration: Effects of a single intravenous administration of heparin or N\u2010acetylheparin 2 hours before regional ischemia and reperfusion","volume":"1","author":"Gralinski MR","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(96)00105-1"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.12.1733"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.6.477"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2004.10.013"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(73)90028-2"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90490-9"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.3184\/003685001783239032"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(62)90247-4"},{"key":"e_1_2_1_45_2","first-page":"2135","article-title":"Interaction of C\u2010reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C\u2010reactive protein with pneumococcal C\u2010polysaccharide and with the choline phosphatides, lecithin and sphingomyelin","volume":"112","author":"Kaplan MH","year":"1974","journal-title":"J Immunol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.4.437"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0022-3565(24)37514-7","article-title":"The semisynthetic polysaccharide pentosan polysulfate prevents complement\u2010mediated myocardial injury in the rabbit perfused heart","volume":"285","author":"Kilgore KS","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0022-3565(24)35004-9","article-title":"Ex vivo reversal of heparin\u2010mediated cardioprotection by heparinase after ischemia and reperfusion","volume":"290","author":"Kilgore KS","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.075283"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010584200"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00292-7"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90431-4"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999309111537"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.50"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63650-4"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2005.05.013"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.19.10301"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-2444-5_16"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42309-5"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000028274"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)01073-5"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(86)90006-7"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90507-S"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.20.2007"},{"key":"e_1_2_1_66_2","first-page":"391","article-title":"Prospective studies of C\u2010reactive protein as a risk factor for cardiovascular disease","volume":"46","author":"Ridker PM","year":"1998","journal-title":"J Invest Med"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910073411506"},{"key":"e_1_2_1_68_2","first-page":"1517","article-title":"Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats","volume":"35","author":"Ruggeri A","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.4049\/jimmunol.137.6.1945","article-title":"Deposition of the terminal C5b\u20109 complement complex in infarcted areas of human myocardium","volume":"137","author":"Schafer H","year":"1986","journal-title":"J Immunol"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R100016200"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00024"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1989.tb22513.x"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2000.278.6.H2084"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1982.tb22140.x"},{"key":"e_1_2_1_75_2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.4049\/jimmunol.128.6.2745","article-title":"Complement\u2010induced solubilization of C\u2010reactive protein\u2010pneumococcal C\u2010polysaccharide precipitates: Evidence for covalent binding of complement proteins to C\u2010reactive protein and to pneumococcal C\u2010polysaccharide","volume":"128","author":"Volanakis JE.","year":"1982","journal-title":"J Immunol"},{"key":"e_1_2_1_76_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.113.1.9","article-title":"Interaction of C\u2010reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: Requirement for human C1q","volume":"113","author":"Volanakis JE","year":"1974","journal-title":"J Immunol"},{"key":"e_1_2_1_77_2","first-page":"133","article-title":"Review: Biology and relevance of C\u2010reactive protein in cardiovascular and renal disease","volume":"30","author":"Westhuyzen J","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_1_78_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4049\/jimmunol.157.1.473","article-title":"CRP\u2010mediated activation of complement in vivo: Assessment by measuring circulating complement\u2010C\u2010reactive protein complexes","volume":"157","author":"Wolbink GJ","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.104.9.974"}],"container-title":["Cardiovascular Drug Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3466.2006.00214.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3466.2006.00214.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T19:19:28Z","timestamp":1736709568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3466.2006.00214.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":78,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1527-3466.2006.00214.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3466.2006.00214.x","archive":["Portico"],"relation":{},"ISSN":["0897-5957","1527-3466"],"issn-type":[{"value":"0897-5957","type":"print"},{"value":"1527-3466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}